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Abstract
Introduction. Fascins are a group of proteins taking part in the maintenance of a proper structure of the cellular 
cytoskeleton. Fascin-1 is an actin-bundling protein present in neurons, fibroblasts, endothelial, smooth muscle, 
dendritic and mesenchymal cells whereas lack of its expression is characteristic of epithelial cells. Fascin-1 
overexpression can be observed in neoplastic cells. Therefore, the aim of this study was to assess the expression 
of Fascin-1 protein in patients with colorectal cancer (CRC) and to analyze associations between Fascin-1 ex-
pression and clinical-pathological parameters.
Material and methods. The study material included postoperative samples (tumor and unchanged colon tissue) ob-
tained from 51 CRC patients. Fascin-1 expression was assessed in the paraffin sections by immunohistochemistry.
Results. A statistically significant correlation was found between the histological type of cancer and the expres-
sion of Fascin-1 (p = 0.012). Increased expression of Fascin-1 in CRC was more frequent in adenocarcinoma 
type without the mucosal component with a better prognosis and decreased expression of this protein correlated 
with infiltration of cancer cells to blood and lymphatic vessels (p = 0.038). 
Conclusions. Our findings indicate a potential role of Fascin-1 in the pathogenesis of colon cancer; however, 
further studies will show whether this protein plays a role in the infiltration of colorectal cancer cells. (Folia 
Histochemica et Cytobiologica 2018, Vol. 56, No. 2, 106–112)
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Introduction
Cancer is a leading cause of death worldwide both in 
high and low developed countries. The incidence of 
colorectal cancer (CRC) rate varies among different 
regions — higher rates are observed in the devel-
oped and industrial countries like Japan, Western 
Europe, and North America, and lower CRC rates 
in the less-developed countries of Eastern Europe, 
Latin America and Asia. In the developing countries 
dietary habits characterized by higher intake of fat, 
fast foods, meat and total calories, along with lack 
of physical activity, high prevalence of obesity and 
genetic factors cause remarkable increase in the 
burden of CRC. Moreover, increasing life expectancy 
and population growth result in longer exposure to 
carcinogenic factors [1].
Most frequently CRC develops on the base of 
adenoma found in the colon mucosa. Adenomas are 
benign lesions which become dysplastic lesions over 
time, resulting in carcinoma. Adenomas or carcino-
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mas are easy to remove in their early stage during 
the colonoscopy. Biological material obtained in this 
procedure is the valuable material for diagnostic and 
screening examination, which is a vital prognostic 
factor in case of CRC detection. Neoplastic process 
lasts a long time before the symptoms of the disease, 
therefore prophylaxis is so important as well as the 
search for new markers detecting cancer lesions and 
new therapeutic targets [2].
Neoplastic processes involve changes in cellular cy-
toskeleton which lead to acquiring by the cancer cells 
ability to migrate. The eukaryotic cellular cytoskeleton 
consists of microfilaments (actin filaments), microtu-
bules and intermediate filaments. Actin is available 
in two forms: monomeric (G-actin) and filamentous 
(F-actin). G-actinin the presence of magnesium ions 
and ATP transforms into the F-actin. F-actin play a 
crucial role in many cellular functions like motility and 
the maintenance of cell shape, polarity and regulation 
of transcription. It is also involved in the formation 
of structures associated with cell migration, such as 
filopodia [3–5]. Fascins are the group of globular pro-
teins responsible for maintenance of a proper struc-
ture of the cellular cytoskeleton and are the main actin 
filament-bundling proteins in filopodia. The genome 
of mammals codes three isoforms of fascin: Fascin-1, 
which occurs physiologically in neurons, fibroblasts, 
endothelial cells, smooth muscles cells, dendrite and 
mesenchymal cells; Fascin-2 found in the retina cells 
and Fascin-3 occurring in the testis [6–8]. In normal 
epithelial cells, Fascin-1 is not expressed, whereas 
its overexpression is observed in the neoplastic cells, 
including CRC cells [7, 9–11]. Fascin-1 has two F-actin 
binding sites. The interactions between Fascin-1 and 
F-actin depend on the activity of protein kinase C al-
pha (PKCa) and GTPases located in the extracellular 
matrix [7]. Fascin-1 binds actin filaments, organizing 
it in the fibers crosslinked collaterally, and also stimu-
lates secretion of growth factors and cytokines by the 
cells [7]. Fascin-1 was shown to bind b-catenin, which 
is responsible for adhesion of cells and belongs to 
a signal pathway of Wnt. Wnt is a group of proteins 
playing an essential role in embryogenesis and car-
cinogenesis [12]. The studies on cell cultures showed 
that Fascin-1 forms filopodia, structures responsible 
for cell migration [11, 13]. Fascin-1 plays a key role in 
these structures and is the only actin-binding protein 
present in the whole length of filopodia. Cells with high 
Fascin-1 expression are higher migratory ability and 
thus are more invasive [6–8, 10, 11]. Jawhari et al. [11], 
studying in vitro epithelial colon cell, demonstrated 
the lack of expression of Fascin-1 in normal cells and 
the presence of Fascin-1 in the cells of inflammatory 
infiltration and cancer cells. The results of their stud-
ies suggest that overexpression of Fascin-1, associated 
with formation of filopodia, may increase migratory 
capability and enhance proliferation of neoplastic 
cells [11].
Therefore, the aim of the present study was to 
evaluate the expression of Fascin-1 in colorectal 
cancer and to analyze associations between Fascin-1 
expression and clinical and pathological parameters. 
Material and methods
Patients. The study material constituted postoperative 
samples obtained from 51 patients (34 men and 17 women) 
diagnosed with colorectal cancer, treated in the Second 
Department of General and Gastroenterological Surgery, 
Medical University of Bialystok (Bialystok, Poland) be-
tween 2005 and 2013. In 29 patients, carcinoma lesions 
were located in the rectum, whereas in 22 patients, they 
were found in other parts of the large intestine. Diagnosis 
of colorectal cancer was established based on the results of 
histopathological examination. The adenocarcinoma type 
without a mucosal component was observed in 41 patients, 
while the mucinous type in 10 patients. The grade of histo-
logical differentiation was moderately differentiated in case 
of 48 patients and poorly differentiated only in 3 patients. 
According to Classification of Malignant Tumors (TNM) 
[14], in one case, the tumor infiltrated the submucosal lay-
er (pT1), in 3 cases, the layer of smooth muscles (pT2), in 
44 cases the tumor infiltrated the subserous layer (pT3), and 
only in 3 cases it infiltrated surrounding organs (pT4). In 
17 patients, metastases were found in surrounding lymphatic 
nodes, while in 10 patients, distant metastases were detected 
in the liver and lungs (Table 1). Additionally, the presence 
of tumor budding was assessed according to Guzińska-Usty-
mowicz [15], while the inflammatory infiltration within the 
tumor and embolisms of neoplastic cells in blood and lym-
phatic vessels were evaluated according to Jass et al. [16]. 
The study was performed after receiving the approval of the 
Bioethical Committee (R-I-002/11/2017) and appropriate 
written informed consent regarding the use of tissue was 
obtained from each patient in the study.
Immunohistochemistry. The expression of Fascin-1 was 
determined in the cancerous tissue and healthy mucosal 
tissue of the large intestine by the immunohistochemical 
method. The examinations were carried out on the paraffin 
blocks with the embedded tissues. Healthy mucosa of the 
large intestine constituting a control group was obtained 
from the fragment of the intestine without inflammation 
or cancer cells, resected during surgery. The tissue material 
was fixed in formalin and embedded in paraffin, then the 
tissue fragments sections were cut into 4 μm thick sections 
and placed on silanized glasses. To prepare for staining, the 
sections were heated up at 60°C for 1 hour. The material 
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was deparaffinized consecutively in xylenes and hydrated 
in alcohols. For antigen retrieval slides were incubated 
in citrate buffer (pH = 6) at 97oC for 20 min and at room 
temperature (RT) for the next 20 min. The activity of en-
dogenous peroxidase was blocked by incubating the sections 
in 3% H2O2 for 5 min. Nonspecific antibody binding was 
blocked by the use of Protein Block (Novocastra, Warsaw, 
Poland) for 5 min. Next, sections were incubated with the 
mouseanti-Fascin-1 antibody (clone #833223, 1:50; R&D 
Systems, Minneapolis, MN, USA) for 60 min. at RT. The 
reaction was visualized with a post-primary reagent (rabbit 
anti mouse IgG, NovoLink Polymer, Novocastra) and DAB 
(3,3’-diaminobenzidine) chromogen (Novocastra). Cellular 
nuclei were stained with hematoxylin; next, slides were 
dehydrated in alcohols, rinsed in xylenes and closed in Cy-
toseal XYL medium (Thermo Scientific, Warsaw, Poland). 
Positive and negative control was performed according to 
the manufacturer’s recommendations. Stained preparations 
were observed under light microscope. The expression of 
Fascin-1 protein was estimated quantitatively based on the 
percentage of immunoreactive cells. Fascin-1 expression was 
qualified as low at < 50% of positively staining cancer cells, 
and as high at ≥ 50% of positively staining cancer cells. At 
the magnification of the microscope × 200, five view fields 
were chosen, in which the percentage of positively staining 
cancer cells was counted and averaged.
Statistical analysis. Statistical analysis was based on 
STATISTICA 12.0 program (StatSoft, Tulsa, OK, USA). 
Spearman’s correlation test was used to determine rela-
tions between Fascin-1 protein expression and clinical and 
pathological parameters. The value p < 0.05 was regarded as 
statistically significant. Missing data were removed in pairs.
Results
The clinical-pathological characteristics of the pa-
tients are presented in Table 1. 
No expression of Fascin-1 protein was observed in 
normal colon mucosa (Fig. 1A). In colorectal cancer, 
Fascin-1 expression was revealed in the cytoplasm of 
cancer cells (Fig. 1B, 1C). Low expression of Fascin-1 
protein was found in 25.5% of cases, while high in 
74.5%. Statistical analysis showed lack of statistically 
significant correlations between Fascin-1 expression 
and age, sex, tumor’s localization, grade of histopatho-
logical differentiation, metastases to surrounding 
lymph nodes and distant metastases, depth of cancer 
cell infiltration in the intestinal wall, inflammatory 
infiltration and the presence of tumor budding. How-
ever, a statistically significant correlation was proven 
between the histological type of a tumor and Fascin-1 
expression (p = 0.012, R = –0.3508). A high expres-
sion of Fascin-1 more frequently occurred in adeno-
carcinoma without the mucosal component (80.49%) 
than in mucocellular cancer (50%). A weak negative 
correlation was shown between cancer cell invasion 
to blood and lymphatic vessels and lack of Fascin-1 
Table 1. Characteristics of the study group
Parameter No. of cases (%)
Age
< 60 9 (17.6)
≥ 60 42 (82.4)
Sex
Male 34 (66.7)
Female 17 (33.3)
Localization
Colon 29 (56.9)
Rectum 22 (43.1)
Adenocarcinoma type
Nonmucinosum 41 (80.4)
Mucinosum 10 (19.6)
Grade of malignancies
2 48 (94.1)
3 3 (5.9)
pT stage
1 1 (1.9)
2 3 (5.9)
3 44 (86.3)
4 3 (5.9)
Lymph node metastasis
Absent 34 (66.7)
Present 17 (33.3)
Distant metastasis
Absent 41 (80.4)
Present 10 (19.6)
Vascular invasion
Absent 28 (56.0)
Present 22 (44.0)
Inflammatory infiltration
0 14 (28.0)
1 16 (32.0)
2 11 (22.0)
3 9 (18.0)
Tumor budding
Absent 19 (38.0)
Present 31 (62.0)
Missing data were removed in pairs.
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expression (p = 0.038, R = –0.2944). In CRC patients 
without infiltration of cancerous cells to the blood and 
lymphatic vessels, a higher expression of Fascin-1 was 
observed, while a lower expression of this protein was 
revealed in the vascular invasion (Table 2). 
Discussion
Colorectal cancer, as one of the most common 
carcinomas, constitutes an important challenge for 
researchers investigating its pathomechanisms and 
clinicians. More specific and sensitive markers of 
neoplastic processes are continuously being searched, 
which would enable early detection of cancer lesions. 
Furthermore, scientists seek new therapeutic targets 
that would improve life quality of CRC patients. In 
patients with diagnosed CRC, researchers frequently 
look for specific proteins in serum and tissue biop-
tates. Numerous data report about Fascin-1, a protein 
maintaining the structure of cytoskeleton, as a new 
potential marker whose expression is found in many 
neoplasms derived from epithelial cells [17, 18]. 
Cancer cells are able to metastasise after obtaining 
the phenotype that facilitates their movement and 
migration by the reconstruction of cell core actin 
filamentous network and formation of cell processes 
called filopodia [19, 20]. This process is accompanied 
by Fascin-1 transcription [17]. Vingjevic et al. [21] 
analyzed function of fascin during filopodia forma-
tion in cell cultures by using RNAi technique. Fascin 
silencing in cell cultures caused 4–5 fold decrease in 
the number of filopodia as well as abnormal morphol-
ogy and organization of actin bundles. Moreover, it 
was found that other actin filaments cross-linkers 
like α-actinin or fibrin could not fully substitute for 
fascin function in vivo. Additionally, these authors 
produced point mutants mimicking the active or 
inactive dephosphorylated serine39 (S39E) states of 
fascin and reported that S29E mutants also inhibited 
filopodia formation. The results of this study strong-
ly suggest that fascin is a specific actin cross-linker 
and plays a crucial role in maintenance stiffness and 
proper elongation and bundling of filopodial actin 
filaments [21].
It was reported that cell lines derived from ade-
nocarcinoma of the colon with Fascin-1 expression 
were characterized by higher invasiveness and metas-
tasizing capacity after transplantation [20], whereas 
the same cell types with a decreased expression of 
Fascin-1 had a reduced capability of migration and 
adhesion [22]. In the animal study, Schoumacher et al. 
[23] proved that conditional expression of Fascin-1 in 
the intestinal epithelium of mice with the Apc-mutat-
ed background resulted in a lower survival rate and 
a higher risk of the tumor growth, accelerated cancer 
progression and led to transformation into invasive 
adenocarcinoma in the intestines [23]. 
The expression of Fascin-1 was also studied in 
other cancers of the gastrointestinal tract. Li et al. 
[24] showed Facin-1 presence of in 95% of pancreatic 
ductal adenocarcinoma cells. In this study, the high 
histoscore significantly correlated with a lower pa-
tients’ survival rate, invasion to blood and lymphatic 
vessels and advanced staging of cancer. Kim et al. [25] 
studied Fascin-1 expression in stomach cancer and 
found that it was associated with patients’ older age, 
male sex, depth of tumor invasion, presence of metas-
tases to lymph nodes, advanced staging of tumor and 
its invasion to the blood and lymphatic vessels [25].
The expression of Fascin-1 was also demonstrated 
in other types of cancers. Similarly, in the studies of 
breast cancer, Yoder et al. [26] proved that increased 
Fascin-1 expression negatively correlated with 
patients’ survival. They found no correlation with 
metastases to lymph nodes, to distant organs or size 
of the tumor. In this group of patients, Fascin-1 ex-
Figure 1. Expression of Fascin-1 protein in colorectal cancer. A. Lack of Fascin-1 immunoreactivity in normal colon mucosa. 
B. Positive expression of Fascin-1 in the signet ring cells of colorectal cancer. C. Fascin-1 immunoreactivity in crypt-like glands 
of colorectal cancer. Immunohistochemical staining of Fascin-1 was performed as described in Methods. Magnification 200×
A B C
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pression correlated with a negative status of estrogen 
and progesterone receptors. Additionally, multifactor 
analysis indicates that Fascin-1 may be an important 
prognostic factor in this type of cancer [26]. In ovar-
Table 2. Correlations between immunohistochemical expression of Fascin-1 in tumor tissue and clinical-pathological pa-
rameters in colorectal cancer patients
Parameter Fascin-1 expression
Low < 50% (%) High ≥ 50% (%) R coefficient P value
Age
< 60 2 (22.22) 7 (77.78)
–0.0567 0.693
≥ 60 11 (26.19) 31 (72.81)
Sex
Male 8 (23.53) 26 (76.47)
–0.0865 0.542
Female 5 (29.41) 12 (70.59)
Localization
Colon 7 (24.14) 22 (75.86)
–0.0671 0.640
Rectum 6 (27.27) 16 (72.73)
Adenocarcinoma type
Nonmucinosum 8 (19.51) 33 (80.49)
–0.3508 0.012
Mucinosum 5 (50.00) 5 (50.00)
Grade of malignancies
2 13 (27.08) 35 (72.92)
0.1602 0.272
3 0 (0.00) 3 (100)
pT stage
1 0 (0.00) 1 (100)
–0.0431 0.764
2 1 (33.33) 2 (66.67)
3 11 (25.00) 33 (75.00)
4 1 (33.33) 2 (66.67)
Lymph node metastasis
Absent 7 (20.59) 27 (79.41)
–0.1770 0.214
Present 6 (35.29) 11 (64.71)
Distant metastasis
Absent 11 (26.83) 30 (73.17)
–0.0438 0.765
Present 2 (20.00) 8 (80.00)
Vascular invasion
Absent 4 (14.29) 24 (85.71)
–0.2944 0.038
Present 9 (40.91) 13 (59.09)
Inflammatory infiltration
0 5 (35.71) 9 (64.29)
0.1735 0.228
1 4 (25.00) 12 (75.00)
2 3 (27.27) 8 (72.73)
3 1 (11.11) 8 (88.89)
Tumor budding
Absent 3 (15.79) 16 (84.21)
–0.1946 0.176
Present 10 (32.26) 21 (67.74)
The expression of Fascin-1 was evaluated on the immunohistochemically stained sections as described in Methods. Spearman’s correlation coefficient 
test was used. Missing data were removed in pairs.
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ian cancer a high expression of Fascin-1 was related 
to more advanced staging of cancer, a low stage of 
histopathological differentiation and a low survival 
rate in patients with mucinous cystadenocarcinoma 
[27]. Lee et al. [28] showed that presence of Fascin-1 
in squamous cancer of the oral cavity had a prognostic 
value and its expression correlated with metastases 
to lymph nodes, a total survival rate and a tumor’s 
growth. All these studies confirm that Fascin-1 influ-
ences the neoplastic process in epithelial cells. 
In multifactorial analyses in advanced colorectal 
cancer it was found that Fascin-1 might be an inde-
pendent prognostic factor [29]. Also other authors 
documented correlations between Fascin-1 expression 
in CRC and clinical and pathological parameters 
[30–33]. In our study, no expression of Fascin-1 was 
observed in the normal cells of colon mucosa, which 
is in accordance with the similar results obtained in 
the studies of other authors [29–31, 33]. The relation-
ship between the histological type of the tumor and 
increased expression of Fascin-1 was noted. More 
frequently the presence of this protein was observed 
in adenocarcinoma cells without the mucosal compo-
nent. Similarly, Puppa et al. [29] and Hashimoto et al. 
[30] reported that more frequent expression of Fas-
cin-1 was found in the same type of cancer. Moreover, 
the presence of Fascin-1 in CRC cells correlated with 
advanced dysplasia and a high stage of histopatholog-
ical differentiation and a tumor’s size [32]. Fascin-1 
immunoreactivity scores were significantly increased 
in CRC with metastases to lymph nodes and advanced 
staging of cancer [33]. 
Puppa et al. [29] suggested that patients at the 
same advancement stage of CRC could be divided into 
categories of the risk of remission and progression of 
the disease according to the Fascin-1 expression. They 
showed a correlation between Fascin-1 expression and 
sex, tumor grade and metastases to lymph nodes and 
distant metastases [29]. In our study, no correlation 
was found between Fascin-1 expression and age, sex, 
tumor location and a grade of histopathological differ-
entiation, metastases to surrounding lymph nodes and 
distant metastases, depth of cancer cell infiltration 
in the intestinal wall, inflammatory infiltration and 
the presence of tumor budding. Our results may be 
a consequence of study limitations (study group size, 
contingency). 
Our study provides an observation between de-
creased expression of Fascin-1 and invasiveness of 
cancer cells to lymphatic and blood vessels. Kim et 
al. [25] showed a relation between the expression 
of Fascin-1 in gastric cancer and lymphovascular 
invasion. Moreover, Yamamoto et al. [34] showed a 
significant correlation between expression of Fascin-1 
in gastrointestinal stromal tumors and blood vessel 
invasion. Since our results are contrary to the other 
reports about the role of Fascin-1 overexpression 
in the invasiveness and migration of cancer cells, it 
is essential to perform further thorough analyses of 
this problem. 
Our studies show that increased expression of 
Fascin-1 was more common in the unfavorable clinical 
type of adenocarcinoma without mucosal component 
which suggests a potential role of this protein in the 
histogenesis of colon cancer. 
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